☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog


Inegy is a new product that containes Simvastatin and Ezetimibe and it is licensed for hypercholesterolaemia.

The combination product would mean that a patient already taking the two separate products, or a patient who is not reaching target on a statin alone could be prescribed a single tablet that would have two cholesterol lowering effects.

However, the combination product cost approximately £8 per month more than the separate ingredients. This is equivalent to an additional 2 patients on treatment with the statin alone.

Action: At this time there can be no good reason to use this product over the separate ingredients, except perhaps for those patients with a known and significant compliance problem.

Share 'Inegy' by emailShare 'Inegy' on FacebookShare 'Inegy' on TwitterShare 'Inegy' on LinkedInShare 'Inegy' on reddit


No Comments to “Inegy”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.